Render Target: SSR
Render Timestamp: 2025-03-06T19:05:19.878Z
Commit: 9fc0f116116d9da247dc8ddd4e5fe811153412e1
XML generation date: 2024-09-30 01:57:58.333
Product last modified at: 2025-01-01T09:05:52.297Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

CLEC2D (E4K1H) Rabbit mAb #24276

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 20-30
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:50

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    CLEC2D (E4K1H) Rabbit mAb recognizes endogenous levels of total CLEC2D protein. Based on the antigen sequence, this antibody is predicted to recognize multiple isoforms of CLEC2D.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human CLEC2D protein.

    Background

    C-type lectin domain family 2 member D (CLEC2D), also known as lectin-like transcript 1 (LLT1) and osteoclast inhibitory lectin (OCIL), is a type II transmembrane C-type lectin receptor primarily expressed upon immune cell activation in T cells, B cells, NK cells, and plasmacytoid and monocyte-derived dendritic cells (1-4). CLEC2D interacts with NKR-P1A (KLRB1, CD161) on NK cells and some subsets of T cells, inhibiting NK cell cytotoxicity while alternatively inducing proliferation and IFNγ production in T cells (2-4). CLEC2D is also expressed by osteoblasts, inhibiting osteoclast formation and bone resorption (5,6). Multiple isoforms of CLEC2D produced by alternative splicing have been identified (7).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.